These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 17503670

  • 1. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.
    Vermeulen JN, Meijer DK, Over J, Lange J, Proost JH, Bakker HI, Beljaars L, Wit FW, Prins JM.
    Antivir Ther; 2007; 12(2):273-8. PubMed ID: 17503670
    [Abstract] [Full Text] [Related]

  • 2. The in vitro anti-HIV efficacy of negatively charged human serum albumin is antagonized by heparin.
    Swart PJ, Sun CS, Kuipers ME, Asuncion C, Josephs S, Smit C, Meijer DK.
    AIDS Res Hum Retroviruses; 1997 May 20; 13(8):677-83. PubMed ID: 9168236
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of anti-HIV activity of succinylated human serum albumin.
    Kuipers ME, vd Berg M, Swart PJ, Laman JD, Meijer DK, Koppelman MH, Huisman H.
    Biochem Pharmacol; 1999 Apr 15; 57(8):889-98. PubMed ID: 10086322
    [Abstract] [Full Text] [Related]

  • 4. Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations.
    Proost JH, Beljaars L, Olinga P, Swart PJ, Kuipers ME, Reker-Smit C, Groothuis GM, Meijer DK.
    Eur J Pharm Sci; 2006 Feb 15; 27(2-3):123-32. PubMed ID: 16219448
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver.
    Jansen RW, Olinga P, Harms G, Meijer DK.
    Pharm Res; 1993 Nov 15; 10(11):1611-4. PubMed ID: 8290473
    [Abstract] [Full Text] [Related]

  • 6. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
    Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DK.
    Mol Pharmacol; 1993 Nov 15; 44(5):1003-7. PubMed ID: 7902528
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of Succinylated Serum Albumin in Wistar Rats and Cynomolgus Monkeys: Implications for Dosage Regimens in the Therapy of HIV Infection.
    Swart PJ, Schutten M, Smit C, van Amerongen G, Proost JH, Osterhaus AD, Meijer DK.
    Drug Deliv; 1996 Nov 15; 3(3):165-71. PubMed ID: 26790912
    [Abstract] [Full Text] [Related]

  • 8. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
    Antimicrob Agents Chemother; 2007 Oct 15; 51(10):3574-81. PubMed ID: 17638699
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
    Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.
    J Clin Virol; 2004 Jun 15; 30(2):183-90. PubMed ID: 15125875
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2186-95. PubMed ID: 12773645
    [Abstract] [Full Text] [Related]

  • 14. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B, TIBET Study Group.
    AIDS; 2007 Jan 11; 21(2):169-78. PubMed ID: 17197807
    [Abstract] [Full Text] [Related]

  • 15. The metabolic fate of the Anti-HIV active drug carrier succinylated human serum albumin after intravenous administration in rats.
    Swart PJ, Kuipers ME, Smit C, Beljaars L, Ter Wiel J, Meijer DK.
    J Drug Target; 2001 Apr 11; 9(2):95-109. PubMed ID: 11697111
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
    Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM.
    Antimicrob Agents Chemother; 2011 Feb 11; 55(2):722-8. PubMed ID: 21078951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.